UCLA study seeks women with recurring breast cancer to test new antibody

July 16, 2003

UCLA's Jonsson Cancer Center is testing an experimental immune system-boosting antibody that could one day help women who have not responded to conventional chemotherapy treatments for metastatic breast cancer.

The Phase I study uses an antibody directed at the MUC1 protein, which is exposed on the surface of cancer cells in more than 90 percent of women who have breast cancer. In normal tissues, MUC1 is a protein that is literally sugar-coated, being completely surrounded by carbohydrate molecules. In rapidly growing cancer cells, the sugar structures do not form correctly and the protein core of MUC1 is exposed. Researchers believe this exposed protein core can become a new target that is vulnerable to attack by antibodies.

In laboratory studies, the antibody called R1550 (formerly Therex) has been shown to bind tightly to MUC1 on cancer cells and then activate immune system cells to kill the cancer. Using antibodies to encourage the body's own immune system to do its job is a different way of fighting cancer. Other targeted therapies help cancer-killing drugs work better, but this study seeks to engage the natural immune system cells to do the killing.

"Our study is a real test of an antibody as immunotherapy for breast cancer. The way this antibody works seems to be dependent upon its ability to engage the immune system after it binds to MUC1 on the tumor cells," said Dr. Mark Pegram, director of the Women's Cancer Program Area at UCLA's Jonsson Cancer Center and principal investigator for the study. "Sadly, women who have not responded to chemotherapy don't have too many other treatment options. We believe this antibody has the potential to be a less toxic alternative to conventional chemotherapy treatment for women with recurrent breast cancer."

The research study is recruiting women volunteers who have already been treated with the chemotherapy drugs Taxol or Taxotere and an anthracycline drug such as Adriamycin, but who have relapsed despite prior treatment.

An earlier study conducted in the United Kingdom showed the antibody was well-tolerated in breast cancer patients.

UCLA's Jonsson Cancer Center is currently the only site in the world testing this new antibody, Pegram said.
-end-
Interested volunteers should call 888-798-0719 to see if they qualify to participate in the study.

For more information about UCLA's Jonsson Cancer Center, visit our Web site at http://www.cancer.mednet.ucla.edu/.

University of California - Los Angeles

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.